jump to navigation

MBBP Client Valeritas Files IPO 02/17/2015

Posted by Morse Barnes-Brown Pendleton in Client News.
Tags: , , , , , ,
add a comment

Valeritas, Inc.

On February 12, 2015, MBBP client Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, filed for a $90 million IPO.

The filing with the SEC arrives one week after insulin pump maker Asante Solutions postponed its proposed $49 million offering.

Valeritas markets a disposable device that delivers basal-bolus insulin therapy for Type 2 diabetes.

More details can be found here or visit www.valeritas.com.

Shannon Zollo to Moderate Panel at TiECON East 05/28/2014

Posted by Morse Barnes-Brown Pendleton in Attorney News, Events, M&A.
Tags: , , , , , , ,
add a comment

Corporate Attorney Shannon ZolloTiECON East, the largest startup conference on the East Coast, is being held at the Cambridge Marriott on May 29th-30th. Entrepreneurs from technology, life sciences, education and cleantech industries attend the two-day conference to learn about the latest trends in innovation, get advice from experienced entrepreneurs, and network to find their next big opportunity. On Friday, May 30th MBBP Attorney Shannon Zollo will be moderating a panel titled “M&A or IPO, That’s the Question” in which distinguished experts will help answer questions such as:

  • How early is too early to start thinking about the Exit?
  • What are the important factors to consider for an exit event, whether IPO or M&A?
  • What steps do you need to take today to ensure the best return for yourself and your investors?
  • Does the type of investor you seek matter?

To learn more about the panel, visit TiECON East.

For more information on the specifics regarding M&A transaction or IPOs please feel free to contact  Shannon Zollo.

Boston Business Journal Revisits Local Biotech IPO’s: “Where are They Now? 03/12/2014

Posted by Morse Barnes-Brown Pendleton in Life Sciences, Public Companies.
Tags: , , ,
add a comment

On March 7, the Boston Business Journal (BBJ) published an article titled “A year of biotech IPOs: Where is their stock price now?” which highlights fourteen local biotech companies that went public last year, ranking them by their stock increase seen since the close of their first day on the market until the March 6 close. A year ago this month, Enanta Pharmaceuticals and Tetraphase Pharmaceuticals, both of Watertown, MA, became the first two Massachusetts biotech firms to go public in what turned out to be the busiest biotech IPO boom in more than a decade.

To see the full list visit the BBJ.

Delaware Legislative Update 12/09/2013

Posted by Morse Barnes-Brown Pendleton in Corporate, Public Companies.
Tags: , , , ,
add a comment

Corporate Attorney Josh FrenchBy: Joshua French

Many times prior to an institutional financing, acquisition or an IPO, a company will review its corporate records and notice that there may be a couple of loose ends to tie up with ratifying board resolutions. While this works for many corporate actions, certain actions are not permissible to be retroactively approved under Delaware law and are void. Among these actions include the issuance of stock that was not authorized under a company certificate of incorporation filed with the Delaware Secretary of State. This means that if shares of stock were issued to stockholders before there were enough shares authorized, that those shares are void and any action taken by those stockholders (for example, electing board members) would also be void. This, obviously, could be very problematic, particularly if the board is no longer controlled by the original stockholders.

Beginning in April 2014, the Delaware General Corporation Law (the DGCL) will allow these types of mistakes to be rectified and will allow for corporations to remedy any actions taken that would otherwise have been deemed void. In order to remedy a defective corporate act, the following steps will need to be taken:

  • The board of directors must pass a resolution ratifying the defective corporate act and stating in detail the defect seeking to be cured.
  • If the resolution would have needed to have been approved by the stockholders, the stockholders must also approve the resolution and the company must provide at least twenty days prior notice of the meeting at which the resolution is to be adopted. The notice must also state that any challenge to the ratification must be brought within 120 days of the date on which the resolution is adopted.
  • If the action being remedied would have required a filing with the Secretary of State of Delaware, then a “Certificate of Validation” must be filed with the Secretary of State. The form of this certificate is currently being prepared by the Secretary of State’s office.
  • If the resolution did not require stockholder approval, the corporation must provide notice of the adoption of the ratification resolution to the stockholders within 60 days of approval. The notice must also that any challenge to the ratification must be brought within 120 days of the date on which the resolution is adopted.

This procedure will not be effective until April 1, 2014, but it may be worthwhile for corporations to consider if there are any actions which may not have been approved properly when completed and contact your law firm to determine whether those actions need to be approved under this new section of the DGCL or if there are steps that can be taken now to ensure that proper corporate approvals had been obtained.

For more information on this topic, please feel free to contact Josh.

JOBS Act: Pathway for Emerging Growth Companies 09/21/2012

Posted by Morse Barnes-Brown Pendleton in Events, Legal Developments.
Tags: , , , , , ,
add a comment

On Tuesday, October 16th Morse, Barnes-Brown & Pendleton, PC and Moody, Famiglietti & Andronico, LLP are holding an informational seminar to discuss the economic basis behind the JOBS Act as well as the specific changes instituted by it. A panel of experts will delve into recent data indicating who is taking advantage of the Act’s provisions and why, and describe the ways in which the new legislation has impacted public filings since its inception.

This seminar will examine the following topic areas:

  • Economic and regulatory drivers that set the stage for the JOBS Act
  • Goals of the JOBS Act in terms of job creation and IPO revitalization
  • Major regulatory changes established by the Act
  • The new concept of the “emerging growth company”
  • Confidential public filing
  • Benefits of going public in today’s market

For more information, directions, or to register, please visit the event page: Exclusive Event – JOBS Act: Pathway for Emerging Growth Companies.

%d bloggers like this: